⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: MEDIUM
Smith & Nephew has integrated AI into its surgical robotics platform (CORI) and wound care analytics, with growing investment in machine learning for orthopedic planning and outcomes prediction. The company continues to expand AI-assisted surgery capabilities though monetization of AI-specific revenue remains nascent relative to its broader product portfolio.
Smith & Nephew is a global medical technology company specializing in orthopedic reconstruction, sports medicine, and advanced wound management. With an overall AI score of 62/100, the company occupies a mid-tier position among healthcare peers, reflecting meaningful but still-developing AI integration across its core business lines. Product AI Integration (65/100) and R&D AI Investment (60/100) represent the strongest dimensions, driven by the CORI surgical robotics platform, which incorporates AI-assisted guidance for implant positioning and surgical planning. Machine learning applications in wound assessment and healing prediction further demonstrate embedded product-level AI. Internal AI Use (58/100) and AI Infrastructure (50/100) score modestly lower, suggesting operational AI deployment lags product-side development. Revenue from AI (35/100) is the weakest dimension, indicating that AI-specific monetization remains nascent within the broader portfolio. A medium disruption threat reflects a balanced position. Smith & Nephew faces competitive pressure from Stryker and Zimmer Biomet, both aggressively advancing surgical robotics AI, yet its established CORI installed base and wound care analytics provide defensible footholds. The company is unlikely to face near-term existential disruption but cannot afford complacency. The primary opportunity lies in accelerating CORI's AI capabilities and translating predictive analytics into premium, outcomes-linked pricing models that convert AI investment into measurable revenue contribution.
Full interactive analysis at RankVis.io